Links from this page to related variants, conditions, drugs and topics are not included for automated readers. Those connections are the Gene Knowledge Graph and are licensed as data: https://www.mygenelog.com/license

← Drugs

Antiseizure

Clobazam (Onfi)

A seizure medicine added to others for Lennox-Gastaut syndrome. In people whose CYP2C19 barely works, its active form reaches about 3 to 5 times the usual level, so the label starts them lower and goes slower.

Chemical structure of Clobazam (Onfi): clobazam, drawn by MyGeneLog™ from PubChem records
Chemical structure of clobazam, drawn by MyGeneLog™ from public PubChem records. Free to reuse non-commercially under CC BY-NC 4.0 with credit to MyGeneLog™.

What this drug connects to

The genes involved

CYP2C19

Epilepsy →

Clobazam (Onfi), added to other treatment for Lennox-Gastaut syndrome, is turned into an active form that CYP2C19 clears. In poor metabolisers, whose CYP2C19 barely works, its US label says that form reaches about 3 to 5 times the usual level, so it starts them at 5 mg a day and raises the dose slowly to half the usual steps, considering the full maximum only from day 21.

US prescribing information for ONFI (clobazam), revised March 2024, sections 2.5 and 12.5. This is the label itself, not a CPIC guideline.

How common these versions are, by ancestry

The share of people who carry at least one copy of each version. For the same medicine, it often differs more than tenfold between groups.

CYP2C19 *2 rs4244285 — a non-working version of the enzyme

Korean
47.7%
East Asian
52.7%
European (non-Finnish)
27.4%
African / African American
32.3%
South Asian
55.4%
Admixed American (Latino)
24.3%

CYP2C19 *17 rs12248560 — a faster version of the enzyme

Korean
1.6%
East Asian
1.9%
European (non-Finnish)
39.2%
African / African American
39.3%
South Asian
29.9%
Admixed American (Latino)
24.8%

Worked out from each group's allele frequency: Korean from the Korean studies published in dbSNP, the rest from gnomAD's ancestry groups (via Ensembl), as the survey defines them, not races. How common a version is in a group says nothing about any one person; only a test does.

Questions about Clobazam (Onfi)

What is clobazam?

Clobazam, sold as Onfi, is a benzodiazepine seizure medicine. In the US it is added to other treatment for seizures in Lennox-Gastaut syndrome, a severe childhood epilepsy, from the age of 2.

What does CYP2C19 have to do with it?

The body turns clobazam into an active form, and CYP2C19 is what clears that form. In poor metabolisers, whose CYP2C19 barely works, the label says the active form reaches about 3 to 5 times the level seen in others.

What does the label say for poor metabolisers?

Start at 5 mg a day and raise the dose slowly, by weight, to half the doses in the usual schedule. From day 21, going up to the full maximum, 20 or 40 mg a day depending on weight, may be considered.

What is the boxed warning?

It is about taking it with opioids, about misuse and addiction, and about dependence and withdrawal, as with other benzodiazepines. It is not about genes. Clobazam should never be stopped suddenly without the prescriber.

Quoting this page

Licensed CC BY-NC 4.0: free to read, share and adapt for non-commercial use, naming MyGeneLog™ and linking the exact page. Commercial use, including training or serving a commercial AI system, needs a licence — https://www.mygenelog.com/license

Clobazam (Onfi). MyGeneLog™. https://www.mygenelog.com/drugs/clobazam

This page is educational and contains no dosing information. Where a clinical guideline covers one of these gene-drug pairs it is written for prescribers and works through validated algorithms alongside clinical monitoring. Nothing here is a reason to start, stop, or change a medication — that conversation belongs with the clinician or pharmacist managing your treatment.